Close menu
- Home
- Coronavirus
- Sectors
- Topics
- HSJ Local
- Comment
-
HSJ Knowledge
- Back to parent navigation item
- HSJ Knowledge
- HSJ Partners
- Covid-19 Resources
- Health Check Podcast
- Immersive features
- Top leader lists
- Roundtables
- HSJ webinars
- Commissions and inquiries
- Supplement Archive
- HSJ Healthcare Partnership Awards
-
Channels and networks
- Back to parent navigation item
- Channels and networks
- Insight and influence
- Events
- Jobs
- Products & Services
- Subscribe
Backlash grows against anti-flu drug's clinical efficacy and cost
By Paul Dinsdale2000-11-30T00:00:00
Senior influenza experts have joined a growing backlash against the anti-flu drug Relenza which they fear could have potentially serious financial effects on the NHS and they claim is of unproven clinical effectiveness.
You need to be signed in to read more
Subscribe for unlimited access
With a HSJ subscription you’ll unlock:
- All of HSJ.co.uk and our HSJ mobile app
- News and insight on all areas of public funded healthcare
- Expert commentary, insight and analysis from industry leaders
- 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics
HSJ is part of Wilmington Healthcare Limited, Beechwood House, 2-3 Commercial Way, Christy Close, Southfields, Essex, SS15 6EF. Company number 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Registered in England and Wales. Company registration 30158470
Site powered by Webvision Cloud